STOCK MARKET BSE NSE

WHO rejects Serum Institute's proposal seeking extension of Covishield's shelf life

The move comes even as India's drug regulator has extended Covishield's shelf life from six to nine months from its manufacturing date.

Published: 08th April 2021 09:45 PM  |   Last Updated: 08th April 2021 09:52 PM   |  A+A-

covidshield

Health workers adminsitering Covishield vaccine (File Photo | Madhav K, EPS)

By PTI

NEW DELHI: The WHO has rejected Serum Institute of India's proposal seeking extension of the shelf life of Oxford-AstraZeneca COVID-19 vaccine, Covishield, from six to nine months, citing insufficient data, sources said.

The WHO has also sought a meeting with Drugs Controller General of India (DCGI) to discuss the matter, they said.

The move comes even as India's drug regulator has extended Covishield's shelf life from six to nine months from its manufacturing date.

In a recent communique to Pune-based Serum Institute of India (SII), the WHO has also asked the firm to formulate the doses with enough titer.

Shelf life is the length of time for which an item remains fit for use.

The DCGI in a letter to SII in February said it has no objection in respect of 'extension of shelf life of Covishield vaccine' in multi-dose glass vial (10 dose-5ml) from six months to nine months.

"You are permitted to apply the shelf life of nine months to unlabelled vials available on hand, subject to the condition that the details of such stock, batch-wise, shall be submitted to this office and Central Drugs Laboratory, Kasauli," DCGI Dr V G Somani had said in the letter.

The DCGI's decision will help health authorities in reducing vaccine wastage.

According to an update by the UK drug regulator dated February 22, the shelf-life of the AstraZeneca COVID-19 vaccine is six months.

Meanwhile, concerns have been raised about the  vaccine as the European Union's health agency concluded a "possible link" between the vaccine and rare blood clots but  stressed that the benefits of the vaccine to protect against COVID-19 continue to outweigh the risks.

The UK's medicines regulator on Wednesday said that under-30s in the country will be offered an alternative to the Oxford-AstraZeneca vaccine due to "evolving evidence" linking it to rare blood clots.

Developed by Oxford University and Swedish-British pharma major AstraZeneca, Covishield is being manufactured by SII.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp